Evenamide
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Evenamide ( ; developmental codes NW-3509 and NW-3509A) is a selective voltage-gated sodium channel blocker, including (and not limited to) subtypes Na v 1.3, Na v 1.7, and Na v 1.8, which is described as an antipsychotic and is under development by Newron Pharmaceuticals as an add-on therapy for the treatment of schizophrenia. The drug has shown efficacy in animal models of psychosis, mania, depression, and aggression. The drug was discovered by Newron Pharmaceuticals SpA, a pharmaceutical company located in Italy. Enigma TRS -1 and -2 Phase 3 trials were announced in late 2025.
Evenamide ( ; developmental codes NW-3509 and NW-3509A) is a selective voltage-gated sodium channel blocker, including (and not limited to) subtypes Na v 1.3, Na v 1.7, and Na v 1.8, which is described as an antipsychotic and is under development by Newron Pharmaceuticals as an add-on therapy for the treatment of schizophrenia. The drug has shown efficacy in animal models of psychosis, mania, depression, and aggression. The drug was discovered by Newron Pharmaceuticals SpA, a pharmaceutical company located in Italy. Enigma TRS -1 and -2 Phase 3 trials were announced in late 2025. NW-3509 - Newron Pharmaceuticals NW-3509 - AdisInsight
Text derived from https://en.wikipedia.org/w/index.php?oldid=1378030809 under CC BY-SA 4.0; modifications have been made.